Form Type: 4

SEC EDGAR Link
Accession Number:0001562180-21-004204
Date:2021-06-10
Issuer: SAGE THERAPEUTICS, INC. (SAGE)
Original Submission Date:

Reporting Person:

STARR KEVIN P
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET CAMBRIDGE, MA 02142

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 76.09 2021-06-10 deemed execution date A 10,000 (a) 2031-06-10 common stock 10,000 $76.09 10,000 direct
Footnotes
IDfootnote
f1 the stock option award was issued pursuant to the sage therapeutics, inc. 2014 stock option and incentive plan in accordance with the terms of the amended and restated non-employee director compensation policy. the option will vest in full upon the earlier to occur of june 10, 2022 or the day immediately prior to the 2022 annual meeting of sage's stockholders, subject to continued service as a director on such date.

Elevate your investments